Thrivent Financial for Lutherans Sells 60,960 Shares of Henry Schein, Inc. $HSIC

Thrivent Financial for Lutherans reduced its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 89.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,083 shares of the company’s stock after selling 60,960 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Henry Schein were worth $470,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Westwood Holdings Group Inc. purchased a new stake in Henry Schein in the 2nd quarter valued at about $20,631,000. AlphaQuest LLC boosted its stake in shares of Henry Schein by 91.8% in the 3rd quarter. AlphaQuest LLC now owns 20,861 shares of the company’s stock worth $1,385,000 after buying an additional 9,987 shares during the last quarter. Berger Financial Group Inc purchased a new position in shares of Henry Schein in the 3rd quarter worth approximately $2,981,000. SVB Wealth LLC bought a new position in shares of Henry Schein in the second quarter valued at approximately $1,415,000. Finally, Brandywine Global Investment Management LLC increased its position in shares of Henry Schein by 5.4% during the second quarter. Brandywine Global Investment Management LLC now owns 79,102 shares of the company’s stock valued at $5,778,000 after acquiring an additional 4,061 shares during the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Performance

Shares of HSIC opened at $77.21 on Wednesday. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.80. The stock’s 50-day simple moving average is $77.25 and its 200 day simple moving average is $71.44. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40. The stock has a market capitalization of $9.09 billion, a price-to-earnings ratio of 24.43, a price-to-earnings-growth ratio of 2.33 and a beta of 0.88.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Evercore upped their price objective on Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Morgan Stanley lifted their price objective on shares of Henry Schein from $55.00 to $58.00 and gave the stock an “underweight” rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Wells Fargo & Company raised their price target on shares of Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $76.42.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.